Dr. med. Alessia Maddalena

Dr. med. Alessia Maddalena

Oberärztin
Fachärztin für Psychiatrie und Psychotherapie
+41449313939
alessia-maddalena
Erwachsenenpsychiatrie und -psychotherapie
2009 Facharzttitel FMH für Psychiatrie und Psychotherapie
2007 Psychotherapie - Fachtitel in kognitiver Verhaltenstherapie, Universität Basel
2000 Doktordiplom der Universität Zürich (Dissertation über Hirntumoren)
1997-1998 Postgraduate Kurs in experimenteller Medizin und Biologie an der Universität Zürich
1996 Eidgenössisches Staatsexamen an der Universität Basel
Seit 2008 Oberärztin Tagesklinik und Ambulatorium, Clienia Psychiatriezentrum Wetzikon
2006-2008 Funktionsoberärztin Tagesklinik, Psychiatrische Privatklinik Sanatorium Kilchberg
2003-2006 Assistenzärztin Psychiatrische Privatklinik Sanatorium Kilchberg
2003 4 monatige Praxisassistenz im Kopfwehzentrum Hirslanden Zürich
2001-2002 Psychiatrische Universitätsklinik Zürich, gerontopsychiatrische Forschungsstation
1999-2001 Psychiatrische Universitätsklinik Zürich, gerontopsychiatrisches Forschungsambulatorium
1998-1999 Universitätsspital Zürich, Abt. für klinische Pharmakologie und Toxikologie
1996-1998 Universitätsspital Zürich, Abteilung für Neuropathologie

1. Maddalena A, Papassotiropoulos A, Gonzalez-Agosti C, Signorell A, Hegi Th, Pasch Th,

Nitsch RM, Hock C. Cerebrospinal Fluid Profile of Amyloid β Peptides in Patients with Alzheimer’s

Disease Determined by Protein Biochip Technology.

Neurodegenerative Dis 2004; 1: 231-235

2. Maddalena A, Papassotiropoulos A, Müller-Tillmanns A, Jung HH, Hegi T, Nitsch RM, Hock C.

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated

tau protein to beta-amyloid peptide42.

Arch Neurol. 2003 Sep;60(9):1202-6.

3. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke

K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos

A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

Neuron. 2003 May 22;38(4):547-54.

4. Hock C, Maddalena A, Raschig A, Müller-Spahn F, Eschweiler G, Hager K, Heuser I, Hampel

H, Müller-Thomsen T, Oertel W, Wienrich M, Signorell A, Gonzalez-Agosti C, Nitsch RM. Treatment

with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42

in patients with Alzheimer's disease.

Amyloid. 2003 Mar;10(1):1-6.

5. Papassotiropoulos A, Streffer JR, Tsolaki M, Schmid S, Thal D, Nicosia F, Iakovidou V, Maddalena

A, Lütjohann D, Ghebremedhin E, Renschler M, Brühl A, Benussi L, Binetti G, Braak H, Nitsch

RM, Hock C. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease

associated with an intronic CYP46 polymorphism.

Arch Neurol. 2003 Jan;60(1):29-35.

6. Wollmer MA, Papassotiropoulos A, Streffer JR, Grimaldi LME, Kapaki E., George P.

Paraskevas GP, Maddalena A, de Quervain D, Bieber C, Umbricht D, Lemke U, Bossardt S,

Degonda N, Henke-Westerholt K, Hegi Th, Jung HH, Pasch Th, Hess K, Hock C, Nitsch RM. Genetic

polymorphisms and cerebrospinal fluid levels of tissue inhibitor of metalloproteinases 1 in sporadic

Alzheimer's disease.

Psychiatr Genet. 2002 Sep;12(3):155-60.

7. Hainfellner JA, Voigtlander T, Strobel T, Mazal PR, Maddalena AS, Aguzzi A, Budka H. Fibroblast

can express glial fibrillary acidic protein (GFAP) in vivo. J. Neuropathol Exp Neurol 2001 May;

60(05):449-61

8. Hock C, Maddalena A, Heuser I, Naber D, Oertel W, von der Kammer H, Wienrich M, Raschig

A, Deng M, Growdon JH, Nitsch RM. Treatment with the selective muscarinic agonist talsaclidine decreases

cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease.

Ann N Y Acad Sci. 2000;920:285-91.

9. Maddalena AS, Hainfellner JA, Hegi ME, Glatzel M, Aguzzi A. No complementation between

TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice.

Brain Pathol. 1999 Oct;9(4):627-37

10. Theurillat JP, Hainfellner J, Maddalena A, Weissenberger J, Aguzzi A. Early induction of angiogenetic

signals in gliomas of GFAP-v-src transgenic mice.

Am J Pathol. 1999 Feb;154(2):581-90.

11. Rovigatti U, Afanasyeva T, Brandner S, Hainfellner JA, Kiess M, Maddalena A, Malin G, Rulicke

T, Steinbach J, Weissenberger J, Aguzzi A. Transgenic mice as research tools in neurocarcinogenesis.

J Neurovirol. 1998 Apr;4(2):159-74

12. Aguzzi A, Maddalena A, Brandner S, Klein M. Molecular pathogenesis of spongiform encephalopathy.

Pathologica 1997 Oct; 89(5): 481-490. Review. Italian.

Poster-Vorstellungen:

1. Maddalena A, Gonzalez-Agosti C, Lomas L, Nybom P, Pasch T, Nitsch RM, Hock C. Analysis

of Aß species and tau by protein chip technology in CSF of patients with Alzheimer’s disease. Society

for Neuroscience, Annual Meeting 2001, San Diego CA

Englisch
Französisch
Italienisch